Corvus Pharmaceuticals Inc. (CRVS)
NASDAQ: CRVSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CRVS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $815.69M
- EPS (TTM)
- -$0.72
- Dividend yield
- None
- 52-week range
- 6.39 – 26.95
- Day range
- 9.56 – 10.03
- Volume / Avg
- 927.52K / 1.05M
- Beta
- —
- Shares outstanding
- 84.35M
52-week range
CRVS stock today
Corvus Pharmaceuticals (CRVS) closed at $9.67 on Nov 20, down 3.40% (-$0.34), versus the S&P 500's 3.70% decline. At this level, CRVS sits near the bottom of its 52-week range of $6.39 to $26.95: 64.1% below the high, set on Jan 23, 2026 and 51.3% above the low. CRVS is up 25.6% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 12.8%.
Corvus Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$0.72), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Corvus Pharmaceuticals
Company profileCorvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of first line renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1 clinical trial for the treatment of non-small cell lung cancer.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Richard A. Miller M.D.
- Headquarters
- South San Francisco, CA
- Employees
- 37
- IPO year
- 2016
- Website
- corvuspharma.com
Financial highlights
Full financialsCorvus Pharmaceuticals reported a net loss of $15.3 million, compared with a loss of $62.3 million a year earlier. Diluted earnings per share came in at -$0.53.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2021 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-15.28M | $-62.29M | $-27.03M | $-41.31M | $-43.24M |
| EPS (diluted) | $-0.53 | $-1.02 | $-0.56 | $-0.89 | $-1.03 |
Analyst forecast
ForecastConsensus (6 analysts)
strong_buy
Avg. price target
$31.50+225.75%
- Strong buy 1
- Buy 5
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-0.12 vs $-0.21
- Surprise
- +42.86%
CRVS news
All CRVS news- Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference in LondonGlobeNewswire
- Corvus Pharmaceuticals Reports Third Quarter 2026 Financial ResultsNasdaq
- Corvus Pharmaceuticals GAAP EPS of -$0.22 misses by $0.02Seeking Alpha
- Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2026 Financial ResultsGlobeNewswire
- Corvus Pharmaceuticals Announces Initial Data from Soquelitinib Clinical Trial in Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) will be Presented at the 68ᵗʰ American Society for Hematology Annual Meeting & ExpositionGlobeNewswire
- Noteworthy Thursday Option Activity: NOW, WOLF, CRVSNasdaqNOW, WOLF, CRVS
Corvus Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PHARPharming Group N.V. ADS | 11.54 | -5.10% | $816.78M | vs CRVS |
| VSTMVerastem Inc. | 6.33 | -7.73% | $797.67M | vs CRVS |
| SNDXSyndax Pharmaceuticals Inc. | 8.72 | -4.49% | $785.05M | vs CRVS |
| IRWDIronwood Pharmaceuticals Inc. Class A | 4.70 | -0.21% | $778.09M | vs CRVS |
| MTRIMentari Therapeutics Inc. | 14.70 | -3.57% | $856.94M | vs CRVS |
| LTGOLatigo Biotherapeutics Inc. | 13.00 | -1.81% | $861.89M | vs CRVS |
| COLLCollegium Pharmaceutical Inc. | 24.72 | -1.94% | $768.18M | vs CRVS |
| ORICOric Pharmaceuticals Inc. | 7.36 | -4.42% | $764.94M | vs CRVS |
Indexes, lists and sector
Corvus Pharmaceuticals stock FAQ
What is Corvus Pharmaceuticals's stock price today?
CRVS last traded at $9.67 as of Nov 20, 4:00 PM EST, down 3.40% on the day. Prices are delayed at least 15 minutes.
Who is Corvus Pharmaceuticals's CEO?
Dr. Richard A. Miller M.D. is the chief executive officer of Corvus Pharmaceuticals Inc., which has about 37 employees.
What is the CRVS 52-week high?
The 52-week high for CRVS is $26.95 and the 52-week low is $6.39. The stock is currently 64.1% below its high.